IN8bio’s (INAB) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of IN8bio (NASDAQ:INAB) in a report issued on Tuesday morning,Benzinga reports. They currently have a $8.00 target price on the stock.

IN8bio Trading Down 4.5 %

INAB opened at $0.30 on Tuesday. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 0.05. The stock’s fifty day moving average is $0.30 and its two-hundred day moving average is $0.63. The company has a market capitalization of $21.47 million, a P/E ratio of -0.39 and a beta of -0.07. IN8bio has a 52 week low of $0.22 and a 52 week high of $2.48.

IN8bio (NASDAQ:INAB) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). Analysts forecast that IN8bio will post -0.56 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in IN8bio stock. Sigma Planning Corp raised its position in shares of IN8bio, Inc. (NASDAQ:INAB) by 42.0% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 851,280 shares of the company’s stock after buying an additional 251,600 shares during the quarter. Sigma Planning Corp owned about 1.82% of IN8bio worth $230,000 at the end of the most recent reporting period. 92.05% of the stock is currently owned by institutional investors and hedge funds.

About IN8bio

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.